Abstract Aims Mineralocorticoid receptor antagonists (MRAs) improve outcomes in patients
with heart failure and reduced left ventricular ejection fraction (HFrEF), but their use is limited …

Aims BAY 94-8862 is a novel, non-steroidal, mineralocorticoid receptor antagonist with
greater selectivity than spironolactone and stronger mineralocorticoid receptor binding …

ABSTRACT Aims Mineralocorticoid receptor antagonists (MRAs) improve outcomes in heart
failure with reduced ejection fraction (HFrEF) but remain underused and are often …

Abstract Aims Mineralocorticoid receptor antagonists (MRAs) are recommended (unless
contraindicated) to all patients with heart failure with reduced ejection fraction (HFrEF) …

The 2016 European Society of Cardiology Heart Failure society as well as the 2016
American Heart Association/American College of Cardiology/Heart Failure Society of …

Mineralocorticoid receptor antagonists (MRAs) improve survival and reduce morbidity in
patients with heart failure, reduced ejection fraction (HF–REF), and mild-to-severe …

Aldosterone is a mineralocorticoid hormone with a well-known effect on the renal tubule
leading to water retention and potassium reabsorption. Other major effects of the hormone …

Aim Mineralocorticoid receptor antagonists (MRAs) improve outcomes in heart failure with
reduced ejection fraction (HFrEF), but are underutilized. Hyperkalaemia may be one reason …

Aims To investigate the safety and potential efficacy of the novel non‐steroidal
mineralocorticoid receptor antagonist finerenone in patients with worsening chronic heart …

Aims Women with heart failure (HF) are under‐represented in individual randomized clinical
trials (RCTs). Little is known about sex‐specific treatment effects in HF medications. We …